e-learning
resources
Vienna 2012
Wednesday, 05.09.2012
Pulmonary circulation: basic mechanisms
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
NMDA-type glutamate receptors contribute to the development of pulmonary hypertension
S.J. Dumas, F. Perros, C. Rücker-Martin, L. Tu, C. Guignabert, E. Gouadon, P. Dorfmüller, M. Humbert, S. Cohen-Kaminsky (Le Kremlin-Bicêtre, Châtenay-Malabry, Le Plessis-Robinson, Clamart, France)
Source:
Annual Congress 2012 - Pulmonary circulation: basic mechanisms
Session:
Pulmonary circulation: basic mechanisms
Session type:
Oral Presentation
Number:
4551
Disease area:
Pulmonary vascular diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
S.J. Dumas, F. Perros, C. Rücker-Martin, L. Tu, C. Guignabert, E. Gouadon, P. Dorfmüller, M. Humbert, S. Cohen-Kaminsky (Le Kremlin-Bicêtre, Châtenay-Malabry, Le Plessis-Robinson, Clamart, France). NMDA-type glutamate receptors contribute to the development of pulmonary hypertension. Eur Respir J 2012; 40: Suppl. 56, 4551
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
From pulmonary gas exchange to the interpretation of arterial blood gases
The physiology of breathlessness
The definition of pulmonary hypertension: history, practical implications and current controversies
Related content which might interest you:
LSC Abstract – Glutamatergic signaling through pulmonary vascular NMDA receptors in pulmonary hypertension
Source: International Congress 2015 – Pulmonary hypertension: promising small molecules
Year: 2015
NMDA receptor activation promotes vascular remodeling and pulmonary arterial hypertension
Source: International Congress 2018 – Pathobiology of pulmonary hypertension
Year: 2018
Potential role of memantine in the prevention and treatment of COVID-19: its antagonism of nicotinic acetylcholine receptors and beyond
Source: Eur Respir J, 56 (2) 2001610; 10.1183/13993003.01610-2020
Year: 2020
Selective
versus
non-selective endothelin receptor antagonists
Source: Annual Congress 2005 - New treatments in pulmonary hypertension
Year: 2005
Overexpression of serotonin receptor 1B (5HT-1B) responsible for overflow induced experimental pulmonary arterial hypertension development
Source: Annual Congress 2003 - Pathophysiology of the pulmonary circulation
Year: 2003
Role of muscarinic receptors in airway inflammation and remodelling
Source: International Congress 2015 – Respiratory research in the Netherlands
Year: 2015
Is there a role for endothelin-1 receptor antagonists in the treatment of lung fibrosis associated with pulmonary hypertension?
Source: Eur Respir J, 52 (2) 1801287; 10.1183/13993003.01287-2018
Year: 2018
Endothelin-a receptor antagonists reduce eNOS gene expression in rats with chronic hypoxic pulmonary hypertension
Source: Eur Respir J 2003; 22: Suppl. 45, 271s
Year: 2003
Endothelin receptor antagonists in pulmonary arterial hypertension
Source: Eur Respir J 2008; 31: 407-415
Year: 2008
The endocannabinoids anandamide and 2-arachidonyl-glycerol (2-AG) induce pulmonary hypertension (PH) in a CB1 receptor independent manner - role of COX-2 and EP1 receptor activation
Source: Eur Respir J 2005; 26: Suppl. 49, 733s
Year: 2005
The serotoninergic receptor subtype 5-HTR1B contributes to the pathogenesis of allergic airway inflammation
Source: Annual Congress 2012 - Cell culture and animal models of lung disease
Year: 2012
Endothelin-1 receptor antagonists prevent the development of pulmonary emphysema in rats
Source: Eur Respir J 2010; 35: 904-912
Year: 2010
NTPDase1/CD39 and aberrant purinergic signalling in the pathogenesis of COPD
Source: Eur Respir J 2016; 47: 254-263
Year: 2016
Cholinergic muscarinic receptors and airway remodelling in severe asthma
Source: International Congress 2018 – Studies on the mechanisms underlying airway disease
Year: 2018
Effects of AT1 receptor blockade on pulmonary and systemic manifestations in a COPD/emphysema mouse model
Source: Annual Congress 2009 - Preclinical models in drug development
Year: 2009
Dual endothelin receptor antagonism: setting standards in PAH
Source: Eur Respir Rev 2008; 17: 13-18
Year: 2007
NMDA receptor crosstalk with PDGFR-β and BMPR2 is involved in smooth muscle cell proliferation in pulmonary arterial hypertension
Source: International Congress 2016 – The nature of pulmonary hypertension
Year: 2016
Role of interleukin-1 receptor 1/MyD88 signalling in the development and progression of pulmonary hypertension
Source: Eur Respir J 2016; 48: 470-483
Year: 2016
NTP42, an antagonist of the thromboxane receptor, attenuates experimentally-induced pulmonary arterial hypertension
Source: International Congress 2019 – Pulmonary hypertension: novelties from the bench
Year: 2019
The role of purinergic P2X
7
receptors on lipopolysaccharide (LPS)-induced lung injury
Source: Annual Congress 2007 - Acute and chronic lung injury and its repair: novel molecular insight
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept